Abstract
We report the experiences of 5 patients taking bedaquiline with delamanid in combination: 1 patient was cured; 3 culture converted, with 2 continuing and 1 changing therapy; and 1 died from respiratory insufficiency. For 2 patients, QT-interval prolongation but no arrhythmias occurred. Use of this therapy is justified for patients with limited options.
KEYWORDS:
Europe; India; Italy; MDR TB; Mycobacterium tuberculosis; Russia; Switzerland; TB; United Kingdom; XDR TB; antimicrobial resistance; bacteria; bedaquiline; combination treatment; delamanid; effectiveness; multidrug resistance; multidrug-resistant tuberculosis; mycobacteria; pulmonary; respiratory infections; safety; the Netherlands; tolerability; tuberculosis
Go to Publication